Evaluation and Modelling of the Performance of an Automated SARS-CoV-2 Antigen Assay According to Sample Type, Target Population and Epidemic Trends

Abstract

The Lumipulse® G SARS-CoV-2 Ag assay performance was evaluated on prospectively collected saliva and nasopharyngeal swabs (NPS) of recently ill in- and outpatients and according to the estimated viral load. Performances were calculated using RT-PCR positive NPS from patients with symptoms ≤7 days and RT-PCR negative NPS as gold standard. In addition, non-selected positive NPS were analyzed to assess the performances on various viral loads. This assay yielded a sensitivity of 93.1% on NPS and 71.4% on saliva for recently ill patients. For NPS with a viral load >103 RNA copies/mL, sensitivity was 96.4%. A model established on our daily routine showed fluctuations of the performances depending on the epidemic trends but an overall good negative predictive value. Lumipulse® G SARS-CoV-2 assay yielded good performance for an automated antigen detection assay on NPS. Using it for the detection of recently ill patients or to screen high-risk patients could be an interesting alternative to the more expensive RT-PCR.

The Detection of SARS-CoV2 Antigen in Wastewater Using an Automated Chemiluminescence Enzyme Immunoassay

“…As a corollary, the SARS-CoV-2 genetic variants may pose challenges in identifying new positives. Remarkably, Yin et al reported that no variation of viral effect was identified in 93 strong positive samples [22] [24]. These findings show that the protein area identified by the CLEIA assay is unaffected by mutations, allowing the identification of all variations investigated in this work.…”

SARS-CoV-2 Surveillance in Hospital Wastewater: CLEIA vs. RT-qPCR

“…The World Health Organization named omicron variants in November 2021, which contain mutations in spike proteins as well, and these variants will have no impact on the CLEIA results [45]. There was no statistically significant difference between the results of strains with mutations and SARS-CoV-2 antigen quantities [46,47].…”